Local Institution

Zhengzhou, Henan 450052

0 studies enrolling now · 6 studies all time

What they study most

Acute Ischemic Stroke, Bladder Cancer, Bladder Tumor, Breast Cancer, Chronic Hepatitis B, Lupus Nephritis, Muscle-Invasive Bladder Cancer, Non-Small-Cell Lung Carcinoma, Transient Ischemic Attack (TIA)

Studies at this site

• Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer — Completed
• A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer — Completed
• A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy — Completed
• A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel — Completed
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis — Stopped early
• Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed